Despite advances in chemotherapy and the emergence of several targeted therapies, including specific inhibitors of FLT3, IDH1/2 and BCL-2, AML remains a highly lethal disorder and new treatments are greatly needed50. The gene discussed is IDH1; the disease is acute myeloid leukemia.